Related Experiment Video
Updated: Sep 18, 2025
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Prognostic value of C-reactive protein in patients with melanoma: a meta-analysis
1Clinical Laboratory, Changxing People's Hospital, Huzhou, Zhejiang, China.
Background:
C-reactive protein (CRP) has been widely investigated for its prognostic value for melanoma, however, findings remained different. Consequently, this meta-analysis was performed for identifying its precise role in forecasting melanoma prognosis.
Methods:
We searched PubMed, Web of Science, Embase and Cochrane Library till 25 January 2025, and computed combined hazard ratios (HRs) and 95% confidence intervals (CIs) for estimating CRP's effect on forecasting overall survival (OS) and progression-free survival (PFS) of melanoma.
Results:
Nineteen studies consisting of 4634 cases were enrolled into the present work. As suggested by our data, higher CRP showed remarkable relation to dismal OS (HR = 2.26, 95% CI = 1.89-2.71, p < 0.001) and inferior PFS (HR = 1.84, 95% CI = 1.13-2.98, p = 0.014) of melanoma patients. Subgroup analyses indicated that CRP had consistent prognostic significance of OS among various subgroups (all p < 0.05). The findings were verified to be reliable by publication bias and sensitivity analyses.
Conclusion:
High CRP remarkably predicts dismal OS and PFS of melanoma cases, which is the promising biomarker used to forecast melanoma prognosis in clinical practice.
